Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK
`
`LITERAL ELEMENT
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`MARK STATEMENT
`
`The table below presents the data as entered.
`
`Entered
`
`87348230
`
`LAW OFFICE 118
`
`https://tmng-al.uspto.gov/resting2/api/img/87348230/large
`
`ATHENEX
`
`YES
`
`YES
`
`The mark consists of standard characters, without claim to any particular font style,
`size or color.
`
`GOODS AND/OR SERVICES SECTION (current)
`
`INTERNATIONAL CLASS
`
`DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases
`
`FILING BASIS
`
`        FIRST USE ANYWHERE DATE
`
`        FIRST USE IN COMMERCE DATE
`
`Section 1(a)
`
`At least as early as 11/02/2015
`
`At least as early as 02/08/2017
`
`GOODS AND/OR SERVICES SECTION (proposed)
`
`INTERNATIONAL CLASS
`
`TRACKED TEXT DESCRIPTION
`
`005
`
`Prescription pharmaceutical products for a variety of diseases; House mark for pharmaceuticals directed to treatment of diseases and disorders
`affecting the circulatory system, digestive system, excretory system, endocrine system, integumentary system/exocrine system, immune
`system and lymphatic system, muscular system, nervous system, renal system and urinary system, reproductive system, respiratory system,
`skeletal system, impacting the blood, brain, heart, lungs, kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder,
`rectum, large intestine, small intestine, gall bladder, hair, skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes,
`spleen, eyes, nose, trachea, esophagus, including anti-infectives, anti-emetics, narcotics/analgesics, pharmaceutical preparations for the
`treatment of infectious diseases, pharmaceutical preparations for the treatment of dermatological conditions, pharmaceutical products for the
`treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`FINAL DESCRIPTION
`
`House mark for pharmaceuticals directed to treatment of diseases and disorders affecting the circulatory system, digestive system, excretory
`system, endocrine system, integumentary system/exocrine system, immune system and lymphatic system, muscular system, nervous system,
`renal system and urinary system, reproductive system, respiratory system, skeletal system, impacting the blood, brain, heart, lungs, kidneys,
`stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder, rectum, large intestine, small intestine, gall bladder, hair, skin,
`nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives,
`anti-emetics, narcotics/analgesics, pharmaceutical preparations for the treatment of infectious diseases, pharmaceutical preparations for the
`treatment of dermatological conditions, pharmaceutical products for the treatment of cancer, anesthesia and sedatives, pain relief,
`antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`FILING BASIS
`
`Section 1(a)
`
`

`

`       FIRST USE ANYWHERE DATE
`
`       FIRST USE IN COMMERCE DATE
`
`ADDITIONAL STATEMENTS SECTION
`
`At least as early as 11/02/2015
`
`At least as early as 02/08/2017
`
`MISCELLANEOUS STATEMENT
`
`        MISCELLANEOUS FILE NAME(S)
`
`       ORIGINAL PDF FILE
`
`       CONVERTED PDF FILE(S)
`       (86 pages)
`
`The following is in response to the Office Action issued June 14, 2019. In
`accordance with the Trademark Examining Attorney's requirements, Applicant has
`attached as Exhibit A catalog and insert pages that support its use of its ATHENEX
`mark as a house mark. It is respectfully requested that the application proceed to
`publication.
`
`mis-3898219243-20191212141714937068_._EXHIBIT_A_-.pdf
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0002.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0003.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0004.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0005.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0006.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0007.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0008.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0009.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0010.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0011.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0012.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0013.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0014.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0015.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0016.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0017.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0018.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0019.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0020.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0021.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0022.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0023.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0024.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0025.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0026.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0027.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0028.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0029.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0030.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xm110\RFR003 1 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0032.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR003 3 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0034.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0035.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0036.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0037.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR003 8 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0039.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0040.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0041 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0042.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0043.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0044.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0045.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0046.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0047.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0048.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0049.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0050.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xm110\RFR005 1 .JPG
`
`
`
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0052.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR005 3 .JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\xm110\RFR0054.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0055.JPG
`
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xmll0\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0057.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR005 8 .JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0059.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR0061 .JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0062.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0063.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\Xml10\RFR0064.JPG
`
`\\TICRS\EXPORT17\IMAGEOL‘T17\873\482\87348230\Xml10\RFR0065.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0030.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0031.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0032.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0033.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0034.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0035.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0036.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0037.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0038.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0039.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0040.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0041.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0042.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0043.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0044.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0045.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0046.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0047.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0048.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0049.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0050.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0051.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0052.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0053.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0054.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0055.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0057.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0058.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0059.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0061.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0062.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0063.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0064.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0065.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0066.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0067.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0068.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0069.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0070.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0071.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0072.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0073.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0074.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0075.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0076.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0077.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0078.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0079.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0080.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0081.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0082.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0083.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0084.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0085.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0086.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348230\xml10\RFR0087.JPG
`
`ATTORNEY SECTION (current)
`
`NAME
`
`ATTORNEY BAR MEMBERSHIP NUMBER
`
`YEAR OF ADMISSION
`
`U.S. STATE/ COMMONWEALTH/ TERRITORY
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`Jacqueline M. Lesser
`
`NOT SPECIFIED
`
`NOT SPECIFIED
`
`NOT SPECIFIED
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`US
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00037
`
`ATTORNEY SECTION (proposed)
`
`NAME
`
`Jacqueline M. Lesser
`
`ATTORNEY BAR MEMBERSHIP NUMBER
`
`YEAR OF ADMISSION
`
`U.S. STATE/ COMMONWEALTH/ TERRITORY
`
`XXX
`
`XXXX
`
`XX
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`United States
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00037
`
`OTHER APPOINTED ATTORNEY
`
`CORRESPONDENCE SECTION (current)
`
`Nancy Rubner Frandsen, Kevin M. Bovard, Lesley M. Grossberg, Lisa Bollinger
`Gehman, and Savannah Merceus
`
`NAME
`
`FIRM NAME
`
`INTERNAL ADDRESS
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`JACQUELINE M. LESSER
`
`BAKER & HOSTETLER LLP
`
`CIRA CENTRE, 12TH FLOOR
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`US
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`099927.00037
`
`CORRESPONDENCE SECTION (proposed)
`
`NAME
`
`FIRM NAME
`
`Jacqueline M. Lesser
`
`BAKER & HOSTETLER LLP
`
`

`

`INTERNAL ADDRESS
`
`CIRA CENTRE, 12TH FLOOR
`
`STREET
`
`CITY
`
`STATE
`
`POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`2929 ARCH STREET
`
`PHILADELPHIA
`
`Pennsylvania
`
`19104-2891
`
`United States
`
`215.568.3100
`
`215.568.3439
`
`BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`AUTHORIZED TO COMMUNICATE VIA EMAIL
`
`Yes
`
`DOCKET/REFERENCE NUMBER
`
`SIGNATURE SECTION
`
`RESPONSE SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`SIGNATORY'S PHONE NUMBER
`
`DATE SIGNED
`
`AUTHORIZED SIGNATORY
`
`CONCURRENT APPEAL NOTICE FILED
`
`FILING INFORMATION SECTION
`
`SUBMIT DATE
`
`TEAS STAMP
`
`099927.00037
`
`/Jacqueline M. Lesser/
`
`Jacqueline M. Lesser
`
`Attorney of record, PA bar member
`
`215.564.2155
`
`12/13/2019
`
`YES
`
`NO
`
`Fri Dec 13 15:06:01 EST 2019
`
`USPTO/RFR-XX.XX.XXX.XXX-2
`0191213150601704574-87348
`230-700575dfdd3ec43d7d7f4
`34b841ee957e847cb52ba145a
`4eef54d47e71736a0bd-N/A-N
`/A-20191212145049597000
`
`Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`To the Commissioner for Trademarks:
`
`Application serial no. 87348230 ATHENEX(Standard Characters, see https://tmng-al.uspto.gov/resting2/api/img/87348230/large) has been
`amended as follows:
`
`CLASSIFICATION AND LISTING OF GOODS/SERVICES
`
`Applicant proposes to amend the following class of goods/services in the application:
`Current: Class 005 for Prescription pharmaceutical products for a variety of diseases
`Original Filing Basis:
`Filing Basis: Section 1(a), Use in Commerce: The applicant is using the mark in commerce, or the applicant's related company or licensee is
`
`

`

`using the mark in commerce, on or in connection with the identified goods and/or services. 15 U.S.C. Section 1051(a), as amended. The mark
`was first used at least as early as 11/02/2015 and first used in commerce at least as early as 02/08/2017 , and is now in use in such commerce.
`
`Proposed:
`Tracked Text Description: Prescription pharmaceutical products for a variety of diseases; House mark for pharmaceuticals directed to treatment
`of diseases and disorders affecting the circulatory system, digestive system, excretory system, endocrine system, integumentary system/exocrine
`system, immune system and lymphatic system, muscular system, nervous system, renal system and urinary system, reproductive system,
`respiratory system, skeletal system, impacting the blood, brain, heart, lungs, kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus,
`testes, bladder, rectum, large intestine, small intestine, gall bladder, hair, skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid,
`lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives, anti-emetics, narcotics/analgesics, pharmaceutical preparations for
`the treatment of infectious diseases, pharmaceutical preparations for the treatment of dermatological conditions, pharmaceutical products for the
`treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory preparations, antiepileptic agents, muscle relaxants
`
`Class 005 for House mark for pharmaceuticals directed to treatment of diseases and disorders affecting the circulatory system, digestive system,
`excretory system, endocrine system, integumentary system/exocrine system, immune system and lymphatic system, muscular system, nervous
`system, renal system and urinary system, reproductive system, respiratory system, skeletal system, impacting the blood, brain, heart, lungs,
`kidneys, stomach, liver, pancreas, mammary glands, ovaries, uterus, testes, bladder, rectum, large intestine, small intestine, gall bladder, hair,
`skin, nails, muscles, bones, joints, tendons, spine, thymus, thyroid, lymph nodes, spleen, eyes, nose, trachea, esophagus, including anti-infectives,
`anti-emetics, narcotics/analgesics, pharmaceutical preparations for the treatment of infectious diseases, pharmaceutical preparations for the
`treatment of dermatological conditions, pharmaceutical products for the treatment of cancer, anesthesia and sedatives, pain relief, antiinflamatory
`preparations, antiepileptic agents, muscle relaxants
`Filing Basis: Section 1(a), Use in Commerce: The applicant is using the mark in commerce, or the applicant's related company or licensee is
`using the mark in commerce, on or in connection with the identified goods and/or services. 15 U.S.C. Section 1051(a), as amended. The mark
`was first used at least as early as 11/02/2015 and first used in commerce at least as early as 02/08/2017 , and is now in use in such commerce.
`The applicant's current attorney information: Jacqueline M. Lesser. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is located at
`
`      CIRA CENTRE, 12TH FLOOR
`      2929 ARCH STREET
`      PHILADELPHIA, Pennsylvania 19104-2891
`      US
`The docket/reference number is 099927.00037.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com
`
`The applicants proposed attorney information: Jacqueline M. Lesser. Other appointed attorneys are Nancy Rubner Frandsen, Kevin M. Bovard,
`Lesley M. Grossberg, Lisa Bollinger Gehman, and Savannah Merceus. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is a member of
`the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
`
`      CIRA CENTRE, 12TH FLOOR
`      2929 ARCH STREET
`      PHILADELPHIA, Pennsylvania 19104-2891
`      United States
`The docket/reference number is 099927.00037.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com
`
`Jacqueline M. Lesser submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest
`court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.
`
`The applicant's current correspondence information: JACQUELINE M. LESSER. JACQUELINE M. LESSER of BAKER & HOSTETLER LLP,
`is located at
`
`

`

`      CIRA CENTRE, 12TH FLOOR
`      2929 ARCH STREET
`      PHILADELPHIA, Pennsylvania 19104-2891
`      US
`The docket/reference number is 099927.00037.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`The applicants proposed correspondence information: Jacqueline M. Lesser. Jacqueline M. Lesser of BAKER & HOSTETLER LLP, is located at
`      CIRA CENTRE, 12TH FLOOR
`      2929 ARCH STREET
`      PHILADELPHIA, Pennsylvania 19104-2891
`      United States
`The docket/reference number is 099927.00037.
`
`The phone number is 215.568.3100.
`
`The fax number is 215.568.3439.
`
`The email address is BHIPDocket@bakerlaw.com; jlesser@bakerlaw.com; jmbarr@bakerlaw.com
`
`ADDITIONAL STATEMENTS
`Miscellaneous Statement
`The following is in response to the Office Action issued June 14, 2019. In accordance with the Trademark Examining Attorney's requirements,
`Applicant has attached as Exhibit A catalog and insert pages that support its use of its ATHENEX mark as a house mark. It is respectfully
`requested that the application proceed to publication.
`
`Original PDF file:
`mis-3898219243-20191212141714937068_._EXHIBIT_A_-.pdf
`Converted PDF file(s) ( 86 pages)
`Miscellaneous File1
`Miscellaneous File2
`Miscellaneous File3
`Miscellaneous File4
`Miscellaneous File5
`Miscellaneous File6
`Miscellaneous File7
`Miscellaneous File8
`Miscellaneous File9
`Miscellaneous File10
`Miscellaneous File11
`Miscellaneous File12
`Miscellaneous File13
`Miscellaneous File14
`Miscellaneous File15
`Miscellaneous File16
`Miscellaneous File17
`Miscellaneous File18
`Miscellaneous File19
`Miscellaneous File20
`Miscellaneous File21
`Miscellaneous File22
`Miscellaneous File23
`Miscellaneous File24
`Miscellaneous File25
`Miscellaneous File26
`
`

`

`Miscellaneous File27
`Miscellaneous File28
`Miscellaneous File29
`Miscellaneous File30
`Miscellaneous File3l
`Miscellaneous File32
`Miscellaneous File33
`Miscellaneous File34
`Miscellaneous File35
`Miscellaneous File36
`Miscellaneous File37
`Miscellaneous File38
`Miscellaneous File39
`Miscellaneous File40
`Miscellaneous File4l
`Miscellaneous File42
`Miscellaneous File43
`Miscellaneous File44
`Miscellaneous File45
`Miscellaneous File46
`Miscellaneous File47
`Miscellaneous File48
`Miscellaneous File49
`Miscellaneous File50
`Miscellaneous File51
`Miscellaneous File52
`Miscellaneous File53
`Miscellaneous File54
`Miscellaneous File55
`Miscellaneous File56
`Miscellaneous File57
`Miscellaneous File58
`Miscellaneous File59
`Miscellaneous File60
`Miscellaneous File6l
`Miscellaneous File62
`Miscellaneous File63
`Miscellaneous File64
`Miscellaneous File65
`Miscellaneous File66
`Miscellaneous File67
`Miscellaneous File68
`Miscellaneous File69
`Miscellaneous File70
`Miscellaneous File7l
`Miscellaneous File72
`Miscellaneous File73
`Miscellaneous File74
`Miscellaneous File75
`Miscellaneous File76
`Miscellaneous File77
`Miscellaneous File78
`Miscellaneous File79
`Miscellaneous File80
`Miscellaneous File81
`Miscellaneous File82
`Miscellaneous File83
`Miscellaneous File84
`
`
`
`Miscellaneous File27
`Miscellaneous File28
`Miscellaneous File29
`Miscellaneous File30
`Miscellaneous File31
`Miscellaneous File32
`Miscellaneous File33
`Miscellaneous File34
`Miscellaneous File35
`Miscellaneous File36
`Miscellaneous File37
`Miscellaneous File38
`Miscellaneous File39
`Miscellaneous File40
`Miscellaneous File41
`Miscellaneous File42
`Miscellaneous File43
`Miscellaneous File44
`Miscellaneous File45
`Miscellaneous File46
`Miscellaneous File47
`Miscellaneous File48
`Miscellaneous File49
`Miscellaneous File50
`Miscellaneous File51
`Miscellaneous File52
`Miscellaneous File53
`Miscellaneous File54
`Miscellaneous File55
`Miscellaneous File56
`Miscellaneous File57
`Miscellaneous File58
`Miscellaneous File59
`Miscellaneous File60
`Miscellaneous File61
`Miscellaneous File62
`Miscellaneous File63
`Miscellaneous File64
`Miscellaneous File65
`Miscellaneous File66
`Miscellaneous File67
`Miscellaneous File68
`Miscellaneous File69
`Miscellaneous File70
`Miscellaneous File71
`Miscellaneous File72
`Miscellaneous File73
`Miscellaneous File74
`Miscellaneous File75
`Miscellaneous File76
`Miscellaneous File77
`Miscellaneous File78
`Miscellaneous File79
`Miscellaneous File80
`Miscellaneous File81
`Miscellaneous File82
`Miscellaneous File83
`Miscellaneous File84
`
`

`

`Miscellaneous File85
`Miscellaneous File86
`
`SIGNATURE(S)
`Request for Reconsideration Signature
`Signature: /Jacqueline M. Lesser/     Date: 12/13/2019
`Signatory's Name: Jacqueline M. Lesser
`Signatory's Position: Attorney of record, PA bar member
`
`Signatory's Phone Number: 215.564.2155
`
`The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a
`U.S. state (including the District of Columbia and any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or
`an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.-licensed attorney not currently associated
`with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a
`signed revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder
`has filed a power of attorney appointing him/her in this matter; or the owner's/holder's appointed U.S.-licensed attorney has filed a power of
`attorney appointing him/her as an associate attorney in this matter.
`
`The applicant is not filing a Notice of Appeal in conjunction with this Request for Reconsideration.
`
`Mailing Address:    JACQUELINE M. LESSER
`   BAKER & HOSTETLER LLP
`   CIRA CENTRE, 12TH FLOOR
`   2929 ARCH STREET
`   PHILADELPHIA, Pennsylvania 19104-2891
`Mailing Address:    Jacqueline M. Lesser
`   BAKER & HOSTETLER LLP
`   CIRA CENTRE, 12TH FLOOR
`   2929 ARCH STREET
`   PHILADELPHIA, Pennsylvania 19104-2891
`
`Serial Number: 87348230
`Internet Transmission Date: Fri Dec 13 15:06:01 EST 2019
`TEAS Stamp: USPTO/RFR-XX.XX.XXX.XXX-2019121315060170
`4574-87348230-700575dfdd3ec43d7d7f434b84
`1ee957e847cb52ba145a4eef54d47e71736a0bd-
`N/A-N/A-20191212145049597000
`
`        
` 
`

`

`EXHIBIT A
`
`

`

`Ampicillin
`for Injection, USP
`
`250 mg per vial
`
`500 mg pervial
`
`1 gram pervial
`
`2 grams per vial
`
`10 grams per vial
`
`|
`
`|
`
`|
`
`|
`
`l
`
`NDC 70860-11245
`
`NDC 70860—ll3—15
`
`NDC 70860—ll4—15
`
`NDC 70860-l15-26
`
`NDC 70860—118—99
`
`ATHENEX AccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`1|
`l;
`‘5 "magmmiul:
`
`1mmummimun
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`
`
`
`
`.IJIIIIIIIIJJ"I"-
`
`v
`
`IIIIIl
`
`

`

`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`for Injection, USP
`
`Ampicillin
`NDC 70860-11245
`
`NDC msmmg
`250 mg per vial
`1 gram per vial
`Zagram per v‘ial
`DESCRIPTION
`GlassVial
`DESCRIPTION
`Glass Vial
`DESCRIPTION
`Class Vial
`DESCRIPTION
`Glass Vial
`
`
`NDC 70860-114-15
`
`
`CONCENTRATION
`250 mg per Vial
`CONCENTRATION
`500 mg per Vial
`CONCENTRATION
`I gram per Vial
`CONCENTRATION
`2 grams per Vial
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`CLOSURE
`20 mm
`
`
`UNITOF SALE
`10 vials
`UNIT OF SALE
`10vials
`UNITOF SALE
`IOVials
`UNITOF SALE
`IOvials
`
`
`
`
`
`
`
`
`Yes BAR CODED Yes BAR CODED Yes BAR CODEDBAR CODED Yes
`
`NDC 70860-11899
`
`10 grams per vial
`Pharmacy Bulk
`Package
`10 grams per VIal
`32 mm
`
`DESCRIPTION
`CONCENTRATION
`CLOSURE
`
`UNIT OF SALE
`
`BAR CODED
`
`1 bottle
`
`Yes
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`PACKAGING & LABELINGr Our proprietary, differentiated
`
`and highly-visible label designs
`can assist pharmacists in
`accurate medication selection.
`
`ccuraSEE”
`
`With a unique label design for every Athenex product, we're ofierlng
`pharmacists added AccuraSEE for your pharmacy— and toryour
`patients' safety, The idea Is simple: ”So what you see is exactly what
`you get."
`
`Athenex,AccuraSEE and all label des gns are ccpyright afAthenex.
`@201 9 Athenex. APD7003170374/19
`
`
`
`thenex
`
`

`

`Azithromycin
`
`for Injection, USP
`
`500 mg pervial
`
`| NDC 70860—IOO—IO
`
`ATHENEX AccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`Single-Dose \fia
`
`INFUSION ONLY
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`

`

`Azithromycin
`
`for Injection, USP
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`NDC 70860-100-10
`
`500 mg per vial
`
`Yes
`
`Class Vial
`
`500 mg per vial
`
`20 mm
`
`10 vials
`
`.
`.
`lmhmmymn
`‘Illgtninu us!
`
`>
`
`DESCRIPTION
`
`CONCENTRATION
`
`CLOSURE
`
`UNIT OFSALE
`
`BAR CODED
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`
`
`
`
`
`Our proprietarydifferentiated and highlyevisible IabeI designs
`CcuraSEE C3” aSSISt Pharmacists in accurate medication seiection.
`PACKAGING 3. LABELING
`With a unique AccuraSEE label design for every Athenex
`product, we’re helping your pharmacyto reduce the risk
`of medication errors.The idea is simple:“So what you see
`
`is exactly wh at you get."
`
`
`
`
`
`Athenex,AccuraSEEand all label deSignsarecopyright afAtheriex.
`©2019 Athenex. APDvOOO3v04v08/19
`
`thenex
`
`

`

`Busulfan
`Injection
`
`60 mg perIO mL | NDC 70860—216—IO
`
`. ATHENEXAccuraSEESM PACKAGING AND LABELING
`
`BIG, BOLD AND BRIGHT —
`TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT
`
`DIFFERENTIATION IN EVERY LABEL,
`DESIGNED TO HELP REDUCE MEDICATION ERRORS
`
`
`
`For Intravenous Infusion Only
`Caution: Must Be Diluted
`BeIore Use
`
`I
`
`
`
`1::mLSinalu-Du-n\llal
`
`.
`
`THE NEXT GENERATION OF PHARMACY INNOVATION
`
`

`

`Busulfan
`
`Injection
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`
`NDC 70860-21640
`
`60 mg per 10 mL DESCRIPTION
`
`Class Vial
`
`6 mg per mL
`
`CONCENTRATION
`CLOSURE
`
`UNIT OFSALE
`
`BAR CODED
`
`20 mm
`
`8Vials
`
`Yes
`
`CHOOSE AccuraSEESM FOR YOUR PHARMACY
`
`
`
`
`
`
`Our proprietarydifferentiated and highlyevisible label designs
`CcuraSEE C3” 355“ Pharmacists in accurate medication selection.
`PACKAGING & LABELING
`With a unique AccuraSEE label design for every Athenex
`product, we’re helping your pharmacyto reduce the risk
`of medication errors.The idea is simple:“So what you see
`
`is exactly wh at you get."
`
`
`
`
`
`Athenex,AccuraSEEand all label desrgnsarecopyright afAthenex.
`©2019 Athenex. APD70056~01703N9
`
`thenex
`
`

`

`
`
`
`
`BUSULFAN Injection
`INDICATION AND USAGE
`- Busulfan injection is indicated for use in combination with
`cycloplrosphamide as a conditioning regimen prior to
`allogeneic hematopoietic progenitor cell transplantation
`forchronic myelogenous leukemia.
`IMPORTANT SAFETY IN FORMATION
`WARNING: MVELOSUPPRESSION
`BUSULFAN INJECTION CAUSES SEVERE AND PROLONGED
`MYELOSUPPRESSION ATTHE RECOMMENDED DOSAGE.
`HEMATOPOIETIC PROGENITOR CELLTRANSPLANTATION IS
`REQUIRED TO PREVENT POTENTIALLY FATAL COMPLICATIONS
`OF THE PROLONGED MYE LOSUPFRESSION
`CONTRAINDICATIONS
`- Busulfan is contraindicated In patrentswrth a
`history of hypersensitivity to any of its components.
`WARNINGS and PRECAUTIONS
`- Myelosuppression: The most frequent serious
`consequence oftreatment with busulfan at the
`recommended dose and schedule is prolonged
`myelosuppreSSion,occurring in all patients (100%).
`Severe granulocytopenia,thrombocytopenia, anemia,
`or any combination thereof may develop. IIematopoietic
`progenitor cell transplantation is required to prevent
`potentially fatal complications. Monitor complete
`blood counts, including white blood cell differentials,
`and quantitative platelet counts daily during treatment.
`Use antibiotic therapy and platelet and red blood cell
`support when medically indicated.
`- Seizures: Seizures have been reported in patients receiving
`highrdose oral busulfan at doses producing plasma drug
`levels srmilartothose achieved followrng the recommended
`dosage ofBusulfan Injection. Initiate phenytoin thera pyor
`any other alternative antieconvulsa nt prophylactictherapy
`(e g,benzodiazepines,valproic acid or levetiracetam) priorto
`busulfan Injection treatment. Use caution when administering
`the recommended dose ofBusulfan Injection to patients
`with a history of a seizure disorder or head trauma or who
`are receiving other potentiallyepileptogenic drugs
`
`To order, call 1-855-273-0154 or visit www.Athenexpharma.com
`ADVERSE REACTIONS
`- The most common adverse reactions (incidence greater
`than 60%) were myelosuppressron, nausea,stomatrtis,
`vomiting, anorexia, diarrhea, insomnia,fever, headache,
`hypomagnesemia, abdominal pain, anxiety, hyperglycemia,
`and hypokalemia.
`OVERDOSAGE
`- There is no known antidote to Busulfan Injection other
`than hematopoietic progenitorc